Deanna M. Glassman

Aug 15, 2024 | digitalcommons.library.tmc.edu | Deanna M. Glassman |Mark Kim |Sunil P. Badal |Meredith Spradlin

Despite modest clinical improvement with anti-vascular endothelial growth factor antibody (AVA) therapy in ovarian cancer, adaptive resistance is ubiquitous and additional options are limited. A dependence on glutamine metabolism, via the enzyme glutaminase (GLS), is a known mechanism of adaptive resistance and we aimed to investigate the utility of a GLS inhibitor (GLSi).